0000000000464879

AUTHOR

Joerg Trojan

showing 4 related works from this author

PD-1 targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicenter real-world cohort

2019

Oncologymedicine.medical_specialtybusiness.industryHepatocellular carcinomaInternal medicineCohortmedicinemedicine.diseasebusinessTargeted immunotherapyZeitschrift für Gastroenterologie
researchProduct

A Phase I dose-escalation study of third-line regorafenib with trifluridine/tipiracil in metastatic colorectal cancer

2021

Aim: To determine a recommended Phase II dose of the oral fluoropyrimidine trifluridine/tipiracil (FTD/TPI) combined with the multi-kinase inhibitor regorafenib (REG) in refractory metastatic colorectal cancer patients. Materials & methods: A conventional 3 + 3 dose finding design was used. FTD/TPI was administered on days 1–5 and 8–12 of a 28-day cycle, REG on days 2–22. Two dose levels were used: FTD/TPI 25 mg/m2 b.i.d. + REG 120 mg/d, then escalated to FTD/TPI 35 mg/m2 b.i.d. + REG 120 mg/d. Results: In total, 12 patients were treated at two dose levels. Three dose-limiting toxicities were observed; all were grade 3 hypertension causally attributed to REG. Recommended Phase II dose …

AdultMale0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyPyrrolidinesMaximum Tolerated DosePyridinesColorectal cancerAdministration OralTrifluridineDrug Administration ScheduleTrifluridine03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRefractoryRegorafenibInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineDose escalationHumansResponse Evaluation Criteria in Solid TumorsAgedTipiracilDose-Response Relationship Drugbusiness.industryPhenylurea CompoundsGeneral MedicineMiddle Agedmedicine.diseaseProgression-Free SurvivalDrug Combinations030104 developmental biologyOncologychemistryThird lineDrug Resistance Neoplasm030220 oncology & carcinogenesisHypertensionToxicityFeasibility StudiesFemaleColorectal NeoplasmsbusinessThyminemedicine.drugFuture Oncology
researchProduct

Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) for resectable esophagogastric cancer: Updated results from multicenter, randomized phase …

2017

0301 basic medicineOncologymedicine.medical_specialtybusiness.industryHematologyOxaliplatin03 medical and health sciences030104 developmental biology0302 clinical medicineGastroesophageal cancerOncologyDocetaxelEsophagogastric cancerFluorouracil030220 oncology & carcinogenesisInternal medicinemedicinebusinessmedicine.drugAnnals of Oncology
researchProduct

PD-8 Regorafenib with TAS-102 in metastatic colorectal cancer patients who progressed after at least two standard therapies: Efficacy and safety resu…

2020

Oncologymedicine.medical_specialtyColorectal cancerbusiness.industryHematologymedicine.diseasePhase i studychemistry.chemical_compoundOncologychemistryInternal medicineRegorafenibmedicinebusinessAnnals of Oncology
researchProduct